WAVE Life Sciences Priced, Nasdaq: WVE

Preclinical biotech developing optimized RNA therapies for rare diseases.

Industry: Health Care

Latest Trade: $18.80 0.00 (0.0%)

First Day Return: 0.0%

Return from IPO: +17.5%

Industry: Health Care

We are a preclinical biopharmaceutical company with an innovative and proprietary synthetic chemistry drug development platform that we are using to design, develop and commercialize a broad pipeline of first-in-class or best-in-class nucleic acid therapeutic candidates. Nucleic acid therapeutics have the potential to address diseases that have been difficult to treat with small molecule drugs or biologics and have emerged as a large and promising class of drugs. We are initially developing nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. Building upon the innovative work of our scientific founders, Gregory L. Verdine, Ph.D. and Takeshi Wada, Ph.D., our preclinical studies have demonstrated that our stereopure nucleic acid therapeutics may achieve superior drug properties as compared to mixture-based nucleic acid therapeutics. Our platform is designed to enable us to rationally design, optimize and manufacture stereopure nucleic acid therapeutics. Further, it has the potential to be used to design therapies that utilize any of the major molecular mechanisms employed by nucleic acid therapeutics, including antisense, ribonucleic acid interference, or RNAi, and exon skipping.
more less
IPO News for WAVE Life Sciences
more
IPO Data
IPO File Date 10/09/2015
Offer Price $16.00
Price Range $15.00 - $17.00
Offer Shares (mm) 6.4
Deal Size ($mm) $102
IPO Data
IPO Date 11/10/2015
Offer Price $16.00
Price Range $15.00 - $17.00
Offer Shares (mm) 6.4
Deal Size ($mm) $102
Underwriters
more
Company Data
Headquarters Singapore, Singapore
Founded 2012
Employees 28
Website www.wavelifesciences.com